Abstract
Aim: To align predicted and measured CYP2C19 phenotype in a South African cohort. Materials & methods: Genotyping of CYP2C192, *3, *9, *15, *17, *27 and *28 was performed using PCR-RFLP, and an activity score (AS) system was used to predict phenotype. True phenotype was measured using plasma concentrations of omeprazole and its metabolite 5′-hydroxyomperazole. Results: Partial genotype-phenotype discrepancies were reported, and an adapted AS system was developed, which showed a marked improvement in phenotype prediction. Results highlight the need for a more comprehensive CYP2C19 genotyping approach to improve prediction of omeprazole metabolism. Conclusion: Evidence for the utility of a CYP2C19 AS system is provided, for which the accuracy can be further improved by means of comprehensive genotyping and substrate-specific modification. ## Citation
Dodgen, Tyren M, Drögemöller, Britt I. Wright, Galen Eb, Warnich, Louise, Steffens, Francois E, Cromarty, A Duncan, Alessandrini, Marco, Pepper, Michael S, “Evaluation of Predictive Cyp2C19 Genotyping Assays Relative to Measured Phenotype in a South African Cohort,” Pharmacogenomics 16, 12(2015): 1343-1354, doi: 10.2217/pgs.15.80